US Cases / Year
~100k
~100,000 new melanoma diagnoses annually in the US; ~8,000 deaths. The mortality-to-incidence ratio has improved dramatically with immunotherapy — more people are living longer with metastatic disease.[1]
What Is It
Definition, mechanism, and the clinical reality of metastatic melanoma at end of life. What the hospice team needs to understand on day one.
5-Year OS — Modern IO
~52%
Nivolumab + ipilimumab at 5 years (CheckMate 067). The most dramatic survival improvement in solid tumor oncology history. In 2010, median OS for metastatic melanoma was 6–9 months.[2]
BRAF Mutation Prevalence
~50%
~50% of cutaneous melanomas harbor BRAF V600E/K mutations, defining the targeted-therapy-eligible population. BRAF status shapes the entire treatment algorithm.[3]
Brain Met Prevalence — Stage IV
40–60%
40–60% of patients with Stage IV melanoma develop brain metastases during their disease course — the defining complication of advanced melanoma and the primary driver of hospice symptom management.[4]
Metastatic melanoma is a malignant neoplasm of melanocytes that has spread beyond the primary cutaneous site to distant organs. It is the most biologically volatile cancer encountered in hospice. The same disease that kills some patients within weeks of diagnosis produces durable complete remissions lasting years in others. Immunotherapy — specifically checkpoint inhibitors targeting PD-1 and CTLA-4 — has transformed the landscape so profoundly that 5-year survival rates were unimaginable just fifteen years ago. Yet the patients who arrive at hospice carry a specific and heavy clinical reality: brain metastases that define the neurological trajectory, immune toxicities from prior immunotherapy that persist long after the last infusion, BRAF-targeted oral therapies that may still be producing measurable disease control, and families who were told — accurately — that the odds were genuinely good.[2]
The most common metastatic sites are brain, lung, liver, bone, and distant skin/soft tissue. Brain metastases are present in 40–60% of Stage IV patients and are the primary driver of neurological morbidity and mortality. Liver metastases with elevated LDH signal rapidly progressive disease. The AJCC 8th edition staging classifies M1d (CNS involvement) as the highest-risk substage. Melanoma's unique immunogenicity — its extraordinarily high tumor mutational burden from UV-induced DNA damage — is both the basis for immunotherapy response and the reason for immune-related adverse events that complicate hospice care for months or years after treatment ends.[5]
🧭 Clinical framing
Metastatic melanoma is the most biologically volatile cancer in hospice. The same disease produces durable complete remissions in some patients and kills others in weeks. Immunotherapy has created a landscape where 52% 5-year survival is real — but the patients who arrive at hospice are the ones for whom that statistic did not hold. They carry the weight of a near-miss cure alongside active immune toxicities, possible ongoing BRAF-targeted therapy, and brain metastases that define every clinical decision. Walk in knowing three things: (1) IO toxicities from prior nivolumab or ipilimumab are active clinical problems requiring ongoing management, (2) dexamethasone for brain edema is probably the most important drug in this patient's regimen, and (3) the family may still be processing the grief of statistics that were genuinely in their favor. This is clinically and ethically complex. Walk in prepared.
"Melanoma patients are different. They walk in knowing the numbers — they've been living inside statistical probability for months or years. Some of them had a complete response and then relapsed. Some watched the scan that was supposed to show shrinkage show growth instead. And all of them know that somebody with their exact diagnosis is alive and cancer-free right now. That near-miss sits in the room with you. Don't pretend it isn't there. Name it: 'You deserved to be in the group that made it.' Then do your job — manage the brain mets, taper the dex correctly, and keep midazolam at the bedside. Clinical excellence is how you honor what almost was."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, molecular profiling, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Dermoscopy & ABCDE criteria: Asymmetry, Border irregularity, Color variation, Diameter >6 mm, Evolution — initial clinical detection method[6]
- Excisional biopsy: Gold standard for primary lesion — shave biopsies are inadequate for staging; Breslow depth is the critical prognostic measurement determining margins and SLNB eligibility[7]
- Sentinel lymph node biopsy (SLNB): For lesions >0.8 mm Breslow depth; positive SLNB upstages to Stage III[8]
- CT chest-abdomen-pelvis with contrast: Metastatic staging for visceral disease burden
- MRI brain with gadolinium: Mandatory in Stage IV — far superior to CT for brain metastasis detection; obtain in any patient with neurological symptoms at any stage[4]
- PET-CT: Metabolic staging and whole-body disease burden assessment; response evaluation
- LDH level: Critical prognostic biomarker — elevated LDH is an AJCC M1c/M1d staging factor; independently predicts poor prognosis regardless of treatment[5]
Molecular Testing
- BRAF V600E/K: Present in ~50% of cutaneous melanoma — defines eligibility for BRAF/MEK inhibitor combinations (dabrafenib+trametinib); V600K slightly less responsive than V600E[3]
- NRAS mutation: ~20% of cutaneous melanoma — BRAF wild-type; no approved targeted therapy; IO is primary approach[9]
- NF1 mutation: ~15% — triple wild-type (BRAF-wt/NRAS-wt/NF1-mut); may have higher IO response rate due to high TMB
- c-KIT mutation: Acral and mucosal melanoma — imatinib occasionally useful in selected patients[10]
- TMB (tumor mutational burden): UV-damaged melanoma has extremely high TMB from UV mutagenesis — may predict IO response; one of the highest TMB cancers[11]
AJCC 8th Edition Staging — Stage IV substages: M1a (distant skin, soft tissue, or lymph node metastases with normal LDH), M1b (lung metastases with normal LDH), M1c (non-CNS visceral metastases including liver, or any distant metastasis with elevated LDH), M1d (CNS involvement — with or without other sites). M1d with elevated LDH carries the worst prognosis. The substage profoundly influences both treatment approach and expected trajectory.[5]
What to Look for in Hospice Records
- Brain metastasis status: Number, size, locations, prior treatment (SRS vs WBRT vs untreated) — this defines the neurological trajectory and seizure risk; determines dexamethasone needs[4]
- LDH trend: Rapidly rising LDH signals accelerating disease and shortened prognosis; normal LDH with stable imaging suggests more indolent course
- BRAF mutation status and targeted therapy history: Is the patient currently on dabrafenib+trametinib? Responding or progressing? This determines whether oral targeted therapy may continue during hospice
- IO treatment history and toxicity record: Which agents received (nivolumab, ipilimumab, pembrolizumab)? Document every prior IO toxicity — colitis, pneumonitis, hepatitis, adrenal insufficiency, hypothyroidism — and current management status including steroid taper plan[12]
- Current steroid regimen: Dexamethasone dose and indication (brain edema vs IO toxicity) — taper plan must be explicit in the care plan; abrupt discontinuation causes crisis
- Performance status trajectory: ECOG trend over last 3 months; rate of functional decline predicts hospice length of stay
💡 For families
Your loved one's melanoma diagnosis was established through skin biopsies, imaging scans, and specialized molecular testing that identified the specific genetic characteristics of the cancer. At this point, the diagnostic workup is complete. The hospice team uses this information to anticipate what symptoms may arise and to prepare the best possible comfort plan. You do not need to worry about further diagnostic testing — our focus now is entirely on comfort, quality of life, and being present with your person.
Causes & Risk Factors
Modifiable and hereditary risk factors, melanoma subtypes, and racial disparities. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Modifiable & Environmental Risk Factors
- UV radiation exposure: Most important modifiable risk factor — both cumulative lifetime UV and intermittent intense exposure causing blistering sunburns; UV causes characteristic C>T transition mutations at dipyrimidine sites defining cutaneous melanoma[13]
- Tanning beds: Artificial UV increases melanoma risk 75% with first use before age 35 — classified as Group 1 carcinogen by IARC[14]
- Occupational outdoor exposure: Chronic sun exposure increases risk of lentigo maligna melanoma on chronically sun-damaged skin
- Geographic latitude: Proximity to equator increases ambient UV exposure and population risk
Hereditary & Non-Modifiable
- Phenotype: Fair skin, blue/green eyes, blonde/red hair, freckles — Fitzpatrick skin types I–II have highest risk due to reduced melanin protection[13]
- Nevi: >50 common nevi doubles risk; atypical/dysplastic nevi are precursor lesions; giant congenital nevi >20 cm carry ~5% lifetime melanoma risk
- Family history: 5–10% of melanoma is familial — first-degree relative with melanoma doubles risk
- CDKN2A: Most common high-penetrance melanoma gene — 30–40% lifetime risk; associated with pancreatic cancer; familial atypical mole and melanoma syndrome (FAMM)[15]
- CDK4, BAP1, MITF, POT1: CDK4 (rare, very high risk); BAP1 (uveal melanoma, mesothelioma, RCC — BAP1 tumor predisposition syndrome); MITF, POT1, TERT (intermediate penetrance)[16]
- Prior melanoma: 8–12x increased risk of second primary melanoma
- Immunosuppression: HIV, post-transplant — increased risk and more aggressive disease course
Melanoma subtypes and their distinct risk profiles: Superficial spreading melanoma (most common — 70%; UV-related; intermittently sun-exposed skin). Nodular melanoma (15–20% — fastest growing; often elevated and uniform color; diagnosis frequently delayed). Lentigo maligna melanoma (5–10% — chronically sun-exposed skin in older patients; face and neck). Acral lentiginous melanoma (2–3% of all cutaneous melanoma, but ~70% of melanoma diagnosed in Black, Asian, and Hispanic patients — subungual and plantar surfaces; not UV-related; often diagnosed at advanced stage due to reduced clinical suspicion in darker-skinned individuals).[17]
❤️ For families: "Why did this happen?"
Melanoma develops because of changes in the DNA of melanocytes — the cells that give skin its color. In many cases, ultraviolet radiation from sun exposure contributes to these changes over a lifetime. But melanoma also occurs in areas that have never seen the sun, in young people who did everything right, and in families with a genetic predisposition that no one could have prevented. Your loved one did not cause this. Sun exposure is a risk factor, not a verdict of blame. What matters now is the quality of the time you have together — not the question of what could have been done differently.
⚕ Clinician note: Genetic counseling & racial disparities
Even at hospice enrollment, referral for genetic counseling is appropriate if germline CDKN2A, BAP1, or other hereditary mutations are identified or suspected. This can save lives in surviving family members — particularly for pancreatic cancer screening in CDKN2A families. Additionally, acral lentiginous melanoma in Black, Hispanic, and Asian patients is systematically diagnosed later with worse outcomes — not because of biological differences but because of reduced clinical suspicion, delayed presentation, and healthcare access inequities. Bob Marley's death from acral melanoma in 1981 remains a powerful teaching case. Address disparities explicitly at the bedside.[18]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Melanoma treatment has undergone the most dramatic revolution in oncology history. Prior to 2011, metastatic melanoma had no effective systemic therapy. Dacarbazine produced response rates of ~10% with no survival benefit. The introduction of ipilimumab (2011), then nivolumab and pembrolizumab (2014–2015), and BRAF/MEK inhibitor combinations transformed the disease. Patients arriving at hospice have typically progressed through one or more of these transformative therapies — understanding what they received, how they responded, and what toxicities they carry is essential to hospice care planning.[2]
Immunotherapy — The Revolution
- Nivolumab + ipilimumab (CheckMate 067): 5-year OS 52%; CR rate 22%; the most effective systemic regimen in melanoma; grade 3–4 immune toxicity in ~55% of patients[2]
- Pembrolizumab monotherapy (KEYNOTE-006): 5-year OS ~34%; better tolerated than combination IO; preferred in patients with comorbidities or advanced age[19]
- Relatlimab + nivolumab (RELATIVITY-047): LAG-3 + PD-1 combination; improved PFS vs nivolumab alone; better tolerability than ipilimumab combination[20]
- Adjuvant IO: Nivolumab or pembrolizumab for resected Stage III/IV — significant recurrence reduction; toxicities persist post-adjuvant treatment
- IO immune toxicity persists 12–18+ months: Colitis, pneumonitis, hepatitis, adrenal insufficiency, hypothyroidism, hypophysitis — these are active problems at hospice enrollment[12]
Targeted Therapy — BRAF-Mutant Melanoma
- Dabrafenib + trametinib (COMBI-d/v): 5-year OS ~34% in BRAF-mutant melanoma; faster initial response than IO (days to weeks vs weeks to months); but nearly all patients eventually develop resistance; median PFS ~11 months[21]
- Vemurafenib + cobimetinib (coBRIM): Alternative BRAF/MEK combination with similar efficacy
- Encorafenib + binimetinib (COLUMBUS): Best tolerability profile among BRAF/MEK combinations[22]
- Response is rapid but resistance is inevitable: Used when rapid tumor response needed for symptomatic or high-burden disease; important as bridge therapy; may continue providing disease control during hospice
Brain Metastasis Management
- SRS (stereotactic radiosurgery): Preferred for ≤4 lesions or oligometastatic CNS disease; melanoma brain mets are radioresistant to conventional fractionation but respond to SRS; concurrent IO with SRS shows synergistic benefit (abscopal effect)[23]
- WBRT: Now rarely used — neurocognitive toxicity and inferiority to SRS; reserved for leptomeningeal disease or diffuse CNS involvement
- IO for brain mets (ABC trial): Nivolumab + ipilimumab achieves intracranial response rates of 26–55% in asymptomatic brain mets; brain mets are no longer an automatic exclusion from IO[24]
- Dexamethasone: Controls peri-tumoral edema; essential bridge during radiation; taper is a primary hospice clinical task
Surgery & Palliative Interventions
- Wide local excision: Margins determined by Breslow depth (1 cm for <1 mm; 2 cm for >2 mm) — completed before hospice enrollment
- Metastasectomy: Melanoma is one of the few cancers where resection of isolated metastases (lung, brain, adrenal) can achieve long-term disease-free survival in selected patients
- Palliative radiation: Highly effective for symptomatic bone mets, cutaneous/subcutaneous deposits, and brain mets — a comfort intervention compatible with hospice goals[25]
- In-transit disease management: Intralesional T-VEC (talimogene laherparepvec), isolated limb perfusion/infusion — for bulky cutaneous or in-transit disease
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
Melanoma is one of the rare cancers where therapy can genuinely produce durable complete remissions even in the metastatic setting. The decision to continue or stop treatment is not binary — it requires precise evaluation of molecular status, prior response, current performance status, and patient goals. The CheckMate 067 data showing 52% 5-year OS with nivolumab + ipilimumab means that melanoma patients are not unreasonable in hoping for long-term benefit. The question is whether the specific clinical situation supports that hope.[2]
- 01BRAF-mutant melanoma with high tumor burden or symptomatic disease, ECOG 0–2: BRAF/MEK inhibitor combination (dabrafenib + trametinib) achieves rapid response rates of 70%+ and symptom relief within days to weeks. Faster than IO for urgent disease control. Appropriate as bridge or primary therapy for patients who need rapid tumor shrinkage.[21]
- 02IO-naive BRAF-mutant melanoma with ECOG 0–1: Nivolumab + ipilimumab offers the highest long-term cure probability (~52% 5-year OS). Superior to targeted therapy for long-term outcomes though slower initial response. First-line IO is preferred when clinical urgency does not require the rapid response of BRAF inhibitors.[2]
- 03Brain metastases — asymptomatic, not requiring steroids: IO (particularly nivolumab + ipilimumab) achieves intracranial response rates of 26–55%. SRS for symptomatic or enlarging brain mets — even in hospice-eligible patients, treating a single symptomatic brain met causing neurological deficit is a comfort intervention, not a disease-treatment decision.[24]
- 04Relatlimab + nivolumab in IO-naive ECOG 0–1: Improved PFS over nivolumab alone; better tolerability than ipilimumab combination. An option for patients who cannot tolerate the toxicity profile of nivolumab + ipilimumab.[20]
- 05Continuation of BRAF/MEK inhibitor in responding patient choosing comfort-focused care: If a patient on dabrafenib + trametinib with stable or responding disease chooses hospice primarily for support and quality of life, the oral targeted therapy may legitimately continue. This is one of the clearest examples where an oral targeted therapy can continue during hospice — coordinate with oncology, document as comfort decision.[21]
- 06Palliative radiation for symptomatic bone mets, cutaneous/subcutaneous deposits, or brain mets: Highly effective comfort interventions. Single-fraction bone radiation, SRS for symptomatic brain mets, and local radiation for ulcerated cutaneous disease are fully compatible with hospice goals.[25]
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Because melanoma has genuine curative potential with immunotherapy, the line between appropriate persistence and futile treatment is harder to draw than in most cancers. Oncologists are understandably reluctant to stop treatment in a disease where late responses occur. But the data are clear on specific thresholds where further systemic therapy produces harm without meaningful benefit.[26]
- 01ECOG ≥3: No evidence of survival benefit from further systemic IO or targeted therapy at ECOG ≥3 in metastatic melanoma. These patients were excluded from every landmark trial. Treatment at this performance status increases toxicity without improving outcomes.
- 02Progression through nivolumab + ipilimumab AND BRAF/MEK inhibitors (if BRAF-mutant): No established standard fourth-line therapy. Response rates to any further agents are <10%. Clinical trial enrollment may be discussed if ECOG 0–1, but outside of trial there is no evidence-based option.[26]
- 03Leptomeningeal melanomatosis: Median survival 4–8 weeks regardless of treatment. Intrathecal therapy is investigational and rarely changes trajectory meaningfully. This is a hospice-defining diagnosis.
- 04Visceral crisis with rapidly rising LDH, hepatic replacement with liver mets, or rapidly progressive diffuse brain metastases: No treatment can reverse the pace of this trajectory. Urgent goals-of-care conversation, not urgent treatment initiation.
- 05Steroid-refractory IO immune toxicity preventing further IO: This is both disease-limiting and treatment-limiting. A patient with severe IO colitis or pneumonitis who cannot receive further IO and has progressed through BRAF-targeted therapy has exhausted standard options.
📋 The BRAF inhibitor continuation question
A melanoma patient on dabrafenib + trametinib with stable disease who chooses hospice for support needs and quality of life is a fundamentally different conversation than a patient with progressive disease on exhausted options. The oral targeted therapy that is maintaining disease control may legitimately continue in hospice — this requires explicit goals-of-care documentation and oncology coordination. It is not abandonment of comfort-focused care. It is precision medicine applied to the hospice setting. Document the clinical rationale explicitly.[21]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
SRS for Symptomatic Brain Mets as Comfort Intervention
Grade ASingle-fraction SRS 15–24 Gy per lesion; planning and delivery in 1–2 sessions
Melanoma brain mets respond to SRS even in patients with otherwise hospice-appropriate disease burden. Treating a single symptomatic brain met causing focal neurological deficit (hemiparesis, aphasia, visual field loss) is a comfort decision, not a disease-treatment decision. Median OS post-SRS for melanoma brain mets is 6–9 months in selected patients. Even in hospice-eligible patients, this conversation belongs at enrollment — refer to radiation oncology if a specific brain met is causing a specific neurological deficit that SRS could palliate. Concurrent IO with SRS may enhance response through abscopal effects.[23]
BRAF/MEK Inhibitor Continuation During Hospice
Grade BDabrafenib 150 mg BID + trametinib 2 mg daily (continue current regimen)
One of the most important and least discussed out-of-the-box discussions in melanoma hospice. If a patient is tolerating dabrafenib + trametinib with stable disease and chooses hospice primarily for support and quality-of-life management, continuing oral targeted therapy is clinically and ethically appropriate. This is not aggressive treatment — it is maintaining disease stability while focusing care on comfort. Coordinate with oncology. Document explicitly in care plan. Cost and pharmacy access may require coordination; some manufacturers offer compassionate use programs.[21]
Acupuncture for IO-Related Arthralgia & Fatigue
Grade B2x/week for 8 weeks initially; maintenance 1x/week; licensed acupuncturist with oncology experience
Immunotherapy-related joint pain and myalgia are among the most common persistent toxicities from nivolumab and ipilimumab. These persist months after IO discontinuation and significantly impair quality of life. Acupuncture achieves meaningful relief in cancer-related arthralgia in multiple RCTs. Particularly valuable in melanoma because steroid use for IO toxicity creates its own side effect burden — acupuncture provides a non-pharmacological alternative for ongoing joint pain management.[27]
MBSR for Near-Miss Grief & IO Toxicity Anxiety
Grade B8-week structured MBSR program; adapted for limited prognosis — abbreviated 4-week versions available
Melanoma patients who almost achieved durable remission and then relapsed develop a specific psychological profile: hypervigilance, scanning anxiety, and profound loss. MBSR specifically reduces cancer-related anxiety and distress in oncology populations. Psycho-oncology referral is particularly important in melanoma — the near-miss grief is unlike any other cancer diagnosis. MBSR also helps manage the anticipatory anxiety associated with ongoing IO toxicity surveillance and the fear of toxicity reactivation.[28]
Palliative Radiation for Cutaneous & Subcutaneous Mets
Grade B8 Gy single fraction or 20 Gy in 5 fractions for bulky cutaneous/subcutaneous deposits
In-transit metastases and bulky subcutaneous deposits can be palliated with local radiation. Reduces pain, ulceration risk, and bleeding from fungating cutaneous melanoma. Visible cutaneous mets cause significant psychological distress — radiation that reduces visible disease burden provides both physical comfort and emotional relief. Low treatment burden compatible with hospice goals. Consider for any patient with symptomatic or cosmetically distressing cutaneous disease.[25]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to metastatic melanoma. Patients will use supplements — this section helps you have the right conversation.
🚨 IO Immune Toxicity — The Defining Supplement Risk in Melanoma
Nivolumab, pembrolizumab, and ipilimumab cause immune-mediated toxicity that persists 12–18 months or longer after discontinuation. Immunostimulant herbs that activate T-cells or upregulate immune checkpoints could reactivate or worsen colitis, pneumonitis, hepatitis, or other IO toxicities that are already in partial remission. Additionally, patients on dexamethasone for brain edema or IO toxicity have steroid-amplified CYP interactions. Verify IO therapy history, current steroid dose, and active IO toxicity status before recommending any immunomodulatory supplement.[12]
"Melanoma patients are some of the most supplement-savvy patients you'll meet — they've been researching immunotherapy and immune boosters since diagnosis. The conversation here is specific: 'I need to know what you're taking because some immune-boosting supplements can actually reactivate the side effects from your immunotherapy — the colitis, the liver inflammation. That's not theoretical. That's real.' Most of them get it immediately. They've lived through IO toxicity. They don't want it back."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger (Zingiber officinale) | Grade B | 1 g/day capsule form; or fresh ginger tea | Nausea from systemic disease, IO toxicity GI effects, and BRAF inhibitor side effects; one of the safest and most useful supplements in this population[29] | Safe; minimal drug interactions; antiplatelet effect negligible at standard doses; safe with dexamethasone; safe with BRAF inhibitors |
| Melatonin | Grade C | 1–5 mg PO at bedtime | Sleep disruption from brain metastases, dexamethasone-induced insomnia, and anxiety; some anti-melanoma signal preclinically; immunomodulatory — but at physiologic doses unlikely to exacerbate IO toxicity[30] | Minimal drug interactions; safe at recommended doses; avoid high doses (>10 mg) in patients with active IO hepatitis; one of the safer supplements in melanoma |
| Turmeric / Curcumin | Grade C | 500 mg–1 g/day standardized extract | Anti-inflammatory properties; may reduce treatment-related joint pain and systemic inflammation[31] | ⚠ CYP3A4 interaction with dabrafenib, trametinib, and dexamethasone — flag if patient is on these agents. Antiplatelet caution in patients on anticoagulation for brain met DVT prophylaxis. Keep doses low. |
| Omega-3 Fatty Acids (EPA/DHA) | Grade C | ≤1 g/day combined EPA+DHA | Anti-inflammatory and cachexia benefit; may reduce cancer-related weight loss and systemic inflammation[32] | ⚠ Antiplatelet caution in patients with brain metastases — intracranial hemorrhage risk. Limit to <1 g/day. Avoid high doses entirely in any patient with brain mets. Monitor for easy bruising. |
🚫 Avoid in Metastatic Melanoma
- Echinacea and all immunostimulant herbs: Absolutely contraindicated in any patient who has received nivolumab, pembrolizumab, or ipilimumab. IO immune toxicities including colitis, pneumonitis, and hepatitis can be reactivated by T-cell stimulating herbs. IO toxicity can persist 12–18+ months after the last dose. This is not theoretical risk — immune stimulation in a patient with subclinical IO colitis can precipitate fulminant colitis requiring hospitalization.[12]
- Astragalus, reishi, turkey tail, and medicinal mushrooms: Marketed as "immune boosting" — which is exactly the problem. Any supplement that upregulates T-cell function or cytokine production risks reactivating IO-mediated organ inflammation. The immune system in a post-IO melanoma patient is not suppressed — it is dysregulated. "Boosting" it is dangerous.
- St. John's wort (Hypericum perforatum): Potent CYP3A4 inducer — dramatically reduces plasma levels of dabrafenib, trametinib, and dexamethasone. Contraindicated in any patient on BRAF/MEK inhibitors or corticosteroids. Can render targeted therapy ineffective.[33]
- High-dose vitamin E (>400 IU/day): Antiplatelet effect increases intracranial hemorrhage risk in patients with brain metastases. Melanoma brain mets already have elevated bleed risk — additional antiplatelet burden is clinically inappropriate.
- Cat's claw, goldenseal: CYP3A4 interactions with targeted therapy and steroids; immunostimulant properties; avoid in all post-IO patients.
Timeline Guide
A guide, not a prediction. Melanoma trajectories vary more dramatically than any other solid tumor — from weeks to years, shaped by IO response, BRAF status, brain metastasis burden, and LDH.
Metastatic melanoma has the widest prognostic range of any solid tumor. A patient with a durable IO complete response may be functionally well for years. A patient with LDH-elevated M1d disease and leptomeningeal involvement may die within weeks. The IO response pattern — complete response, partial response, stable disease, or progression — is the single most important determinant of trajectory. Brain metastasis burden and LDH trend are the next most important. Use this timeline as a framework, not a calendar.[2]
YRS–
MOS
MOS
IO Response Phase — Stage IV with Active Treatment
- This phase defines the difference between melanoma and every other cancer: a patient on nivolumab + ipilimumab with a complete or major partial response may be functionally well for 2–3+ years; some achieve durable complete remission and are effectively cured[2]
- Brain met monitoring (MRI every 3 months) is essential even in responding patients — new CNS disease can emerge while systemic disease is controlled
- IO toxicities may emerge at any point during this phase — colitis, pneumonitis, hepatitis, endocrinopathies; some appear months after treatment ends
- BRAF-mutant patients on targeted therapy may show rapid initial response with excellent functional status, but resistance builds — median PFS on BRAF/MEK is ~10–12 months[21]
- Palliative care integration should begin at Stage IV diagnosis — the possibility of cure makes this conversation feel premature; it is not
MOS–
1 YR
1 YR
IO Progression or BRAF Inhibitor Resistance — Second-Line Therapy
- IO progressors: BRAF/MEK inhibitor if BRAF-mutant and not previously used; clinical trial if available; second IO attempt rarely effective after combination IO failure
- BRAF inhibitor progressors: IO (nivolumab + ipilimumab) if not previously used — IO after BRAF may be less effective due to immune changes from targeted therapy[34]
- Brain mets developing or progressing — SRS considered for oligometastatic CNS disease; dexamethasone initiated or increased
- LDH beginning to rise; performance status declining from ECOG 0–1 toward ECOG 2
- IO toxicities from prior treatment may be ongoing — steroid tapers, hormone replacement, GI management
- This is the palliative integration window most commonly missed — patient still has options, but the trajectory is clear
WKS–
MOS
MOS
Progression Through Available Lines — Hospice Transition
- Brain mets progressing despite SRS or too numerous for further SRS; ECOG declining to 2–3
- LDH rapidly rising; liver mets accumulating with rising bilirubin and transaminases
- Visceral crisis possible — rapid hepatic failure, hemorrhagic brain met, leptomeningeal disease
- Hospice enrollment most appropriate at this transition — goals-of-care conversation focuses on what comfort looks like
- IO toxicity management ongoing — steroid tapers, levothyroxine, hydrocortisone must continue
- BRAF inhibitor continuation decision: if stable on targeted therapy, may continue during hospice; if progressing, discontinuation appropriate
DAYS–
WKS
WKS
Active Dying — Neurological Decline Dominant
- Brain metastasis neurological deficits dominant — focal weakness, aphasia, cognitive changes, personality alteration, progressive somnolence
- Dexamethasone maintaining baseline function; dose that preserves neurological status is the right dose — do not taper at this stage
- Seizure risk elevated — levetiracetam continues; midazolam drawn and at bedside from enrollment[35]
- Liver failure from hepatic mets: jaundice, coagulopathy, encephalopathy layered on brain met effects
- Convert all oral medications to SQ/rectal/buccal routes as swallowing fails
- Family education: personality changes are the disease, not the person; prepare for seizure possibility; review emergency medication protocol
HRS–
DAYS
DAYS
Final Hours
- Cheyne-Stokes or agonal breathing; mandibular breathing; mottling of knees and feet
- Unresponsive or minimally responsive — auditory awareness may persist; continue speaking to the patient
- Hemorrhagic brain met event possible — sudden headache, loss of consciousness, seizure; midazolam immediately; this is the event the family was prepared for at enrollment[35]
- Melanoma-specific: cutaneous mets may bleed or weep — dark towels at bedside; gentle wound care; minimize visual distress for family
- Continue all comfort medications: morphine/hydromorphone for pain and dyspnea; midazolam for agitation/seizure; glycopyrrolate for secretions
- Presence matters more than any medication in these hours. Be in the room. Say what needs to be said.
Medications to Anticipate
Symptom-targeted pharmacology for metastatic melanoma. IO toxicity management, brain met seizure control, steroid taper, and comfort kit essentials.
🚨 Two Unique Pharmacological Realities in Melanoma Hospice
IO immune toxicities and BRAF inhibitor continuation define melanoma hospice pharmacology. Patients may arrive on dexamethasone for brain edema or IO toxicity requiring precise taper management. BRAF/MEK inhibitors may be continuing for disease control. IO toxicity organ-specific management (colitis, pneumonitis, hepatitis, adrenal insufficiency, thyroiditis, hypophysitis) may be ongoing and must be explicitly addressed in the care plan at enrollment. Abrupt discontinuation of corticosteroids for IO toxicity causes adrenal crisis.[12]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Dexamethasone | Corticosteroid / Brain edema | 4–8 mg PO/IV BID | The most important drug in melanoma brain met management. Reduces peri-tumoral edema and maintains neurological function. Taper guided by neurological status, not calendar. Abrupt discontinuation causes acute neurological deterioration. Also used for IO toxicity — adrenal insufficiency requires hydrocortisone replacement, not dexamethasone, unless acute crisis.[36] Monitor glucose; PPI for GI protection; taper plan explicit in care plan from day one |
| Morphine / Oxycodone | Opioid / Pain + Dyspnea | 2.5–5 mg PO q4h; SQ conversion as oral fails | Bone met pain, soft tissue invasion, neuropathic pain from brain mets, dyspnea from pulmonary mets or lymphangitic carcinomatosis. Titrate to effect. SQ morphine at 50% of oral dose. Ensure bowel regimen on day one.[37] |
| Levetiracetam | Anticonvulsant / Seizure prophylaxis | 500–1000 mg PO BID | Melanoma brain mets have elevated seizure risk. SQ route not available — convert to rectal valproate or buccal/intranasal midazolam for seizure rescue as swallowing fails. No CYP interactions — ideal in patients on dexamethasone and BRAF inhibitors.[35] Dose-reduce in renal impairment; monitor for behavioral side effects |
| Midazolam | Benzodiazepine / Seizure rescue, agitation | 5–10 mg SQ/IM for acute seizure; 2.5–5 mg SQ PRN agitation | Seizure rescue, brain met neurological emergency, terminal agitation. ⚠ Must be drawn, labeled, and at bedside from day one of enrollment for any patient with brain metastases. Family education on administration is non-negotiable. Also used for refractory dyspnea and terminal restlessness.[37] |
| Prednisone / Methylprednisolone | Corticosteroid / IO colitis | 1–2 mg/kg/day; taper over 4–8 weeks | IO colitis management — do not taper too fast; IO colitis rebounds. If patient arrives on steroids for IO colitis, coordinate taper with oncology. Abrupt discontinuation precipitates severe diarrhea, abdominal pain, and dehydration. Taper by 10 mg/week for prednisone; individualize based on symptom recurrence.[12] |
| Levothyroxine | Thyroid replacement / IO thyroiditis | 50–100 mcg PO daily | IO-related thyroiditis causes permanent hypothyroidism in ~10–15% of patients on nivolumab ± ipilimumab. This is a permanent replacement — do not discontinue at hospice enrollment. Stopping levothyroxine causes fatigue, constipation, cold intolerance, and cognitive slowing that are reversible but add unnecessary suffering.[38] |
| Hydrocortisone | Adrenal replacement / IO adrenal insufficiency | 20 mg AM / 10 mg PM (physiologic replacement) | IO-related hypophysitis or primary adrenal insufficiency from checkpoint inhibitors. This is permanent cortisol replacement — not anti-inflammatory dosing. ⚠ Abrupt discontinuation causes adrenal crisis: hypotension, vomiting, confusion, shock. Stress-dose with hydrocortisone 50–100 mg IV/IM for acute illness, surgery, or active dying phase.[38] |
| Haloperidol | Antipsychotic / Delirium, nausea | 0.5–2 mg PO/SQ q4–8h | First-line for delirium from brain mets, metabolic encephalopathy. Also effective antiemetic for opioid-induced and CNS-mediated nausea. Low QTc risk at hospice doses. Preferred over atypicals for simplicity in hospice setting. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Family education: secretion noise sounds worse than it feels for the patient. |
| Ondansetron | 5-HT3 antagonist / Nausea | 4–8 mg PO/SQ q8h PRN | Adjunct antiemetic — particularly useful for chemotherapy/IO-related nausea and hepatic capsular stretch nausea from liver mets. Constipating — ensure bowel regimen. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adapted · Melanoma-specific branchesSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Melanoma
Midazolam 5 mg/mL — drawn, labeled, at bedside from day one for any patient with brain metastases. Seizure or hemorrhagic brain event can occur without warning. The family must know where it is, when to use it, and that the nurse has been called. Morphine SQ for pain and dyspnea breakthrough. Haloperidol SQ for delirium/agitation. Glycopyrrolate SQ for secretions. Dexamethasone injectable for neurological crisis (acute brain edema worsening). Hydrocortisone 100 mg IM if patient has IO adrenal insufficiency — for adrenal crisis management. Have all emergency medications drawn and labeled before the crisis. Not during it.[37]
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience with metastatic melanoma.
1
IO immune toxicities are active clinical problems at enrollment
Patients who received nivolumab + ipilimumab may have ongoing colitis, pneumonitis, hepatitis, adrenal insufficiency, or hypothyroidism. These are not resolved when IO is stopped — they persist for 12–18+ months. At enrollment, explicitly document every prior IO toxicity, its current management status, and the steroid taper plan if applicable. Colitis requires a multi-week steroid taper. Adrenal insufficiency requires permanent cortisol replacement. Hypothyroidism requires permanent levothyroxine. Abrupt steroid discontinuation in a patient with IO-related adrenal insufficiency causes acute crisis — hypotension, vomiting, confusion — that is both preventable and cruel.[12]
2
Dexamethasone taper for brain mets is a primary clinical task
Patients on dexamethasone for brain edema are steroid-dependent. The dose that maintains neurological function must be identified and not reduced faster than the clinical picture allows. A patient whose speech or motor function returns with a dexamethasone dose increase needs the dose that maintains that function. Taper is guided by neurological status, not by calendar. A patient who was speaking at dex 8 mg BID and lost speech at 4 mg BID needs 8 mg BID back — today, not at the next visit. Abrupt discontinuation causes acute neurological deterioration that is reversible but traumatic for patient and family.[36]
3
Melanoma brain mets bleed
Unlike most cancer brain mets, melanoma is particularly prone to intracranial hemorrhage. The melanin pigment and neovascularity of melanoma brain mets create friable vessels with elevated spontaneous hemorrhage risk. A patient with multiple brain mets has a meaningfully elevated risk of sudden hemorrhagic event — acute headache, sudden loss of consciousness, seizure. The family must understand this before it happens. Midazolam at the bedside from enrollment, not from the first sign of deterioration. Have the conversation: "If your loved one suddenly loses consciousness or has a seizure, this is what to do, and this is what it means."[35]
4
BRAF inhibitor continuation is a legitimate comfort conversation
If a BRAF-mutant patient is on dabrafenib + trametinib with stable or responding disease and chooses hospice primarily for support and quality of life rather than for disease progression, continuing the oral targeted therapy is clinically and ethically appropriate. This is not choosing treatment over comfort. It is maintaining disease stability while focusing care on quality of life. Document the clinical rationale, coordinate with oncology, address cost and pharmacy access, and ensure the care plan explicitly notes this as a comfort-aligned decision. This is one of the most important nuanced conversations in melanoma hospice.[21]
5
Racial disparities in melanoma require active clinical attention
Acral lentiginous melanoma in Black, Hispanic, and Asian patients is systematically diagnosed at later stages with worse outcomes. These patients face a double inequity: delayed diagnosis due to lower clinical suspicion for melanoma in darker-skinned individuals, and then reduced access to immunotherapy clinical trials that have been predominantly studied in white populations. At the hospice bedside, ensure equitable pain management, recognize that culturally specific grief patterns may differ from institutional norms, and understand that the patient's experience of the healthcare system may include justified mistrust. Ask. Listen. Do not assume.[18]
"The number one mistake I see with melanoma patients in hospice: inheriting a dexamethasone dose with no taper plan. The patient is on 8 mg BID for brain mets, and nobody wrote down why, what the target is, or how to get there. Then the on-call nurse drops it to 4 mg because 'we should taper steroids,' and the patient loses the ability to speak overnight. Get the dex plan on paper at enrollment. Make it specific. Make it neurological-function-driven. And if you're the on-call nurse, do not change the dex dose without talking to the primary team."
— Waldo, NP
Psychosocial & Spiritual Care
Near-miss grief, brain met personality change, IO iatrogenic grief, identity and skin, and family structure. The symptom burden you can't see on a vitals sheet.
Metastatic melanoma creates a psychosocial landscape unlike any other cancer diagnosis. The IO revolution has produced genuine hope — 52% 5-year survival with combination immunotherapy — and genuine grief when that hope is not realized. Patients who arrive at hospice after melanoma treatment carry specific emotional wounds that require specific clinical attention. The grief is not generic. The family dynamics are not standard. And the brain metastases that define the disease trajectory create a uniquely devastating form of anticipatory loss.[39]
The Near-Miss Grief
Melanoma has the most dramatic IO response statistics of any cancer. Patients who enrolled on nivolumab + ipilimumab knowing the 52% 5-year survival data and then progressed carry a specific grief of the near-miss. They were in the half that did not make it through. That is a mathematically specific and emotionally devastating grief that is unlike the grief of any other cancer diagnosis where cure was never realistically offered. Name it explicitly at the bedside:
"You went into this knowing the odds were genuinely good. You deserved to be in the group that made it. That you are not is a specific injustice and a specific grief. I want to acknowledge it."
This acknowledgment is therapeutic in itself. It validates what the patient already knows: that statistics were in their favor, and that outcome does not reflect effort, compliance, or worthiness. Some patients feel guilt — as if they somehow failed the treatment. Address this directly: "The treatment did not fail you, and you did not fail the treatment. Biology is not merit-based."[40]
Brain Metastasis & Personality Change — Ambiguous Loss
The Person Before the Brain Mets
Frontal and temporal brain metastases cause personality changes, behavioral disinhibition, memory loss, and emotional dysregulation that families experience as losing the person before they die. The patient may become impulsive, say inappropriate things, fail to recognize family members, or exhibit emotional flatness that feels like withdrawal. Use the concept of ambiguous loss — the person is physically present but psychologically changed.
Validate the family's grief about the person they knew before the brain mets: "The person you are seeing now is not the person you married / raised / loved for decades. That change is the brain metastases. It is a loss that you are already grieving, and it is appropriate to grieve it."[41]
IO Toxicity & Iatrogenic Grief
Patients who developed severe IO toxicity — colitis requiring ICU admission, pneumonitis requiring ventilation, hepatitis requiring hospitalization — may feel that the treatment supposed to save them nearly killed them. Some stopped IO because of toxicity and then progressed. This is a specific iatrogenic grief:
"The treatment caused harm while it was trying to cure you. That is not fair and it is not your fault."
Acknowledge that the medical system both helped and harmed. This is not anti-treatment language — it is honest language that gives the patient permission to hold both realities simultaneously.[12]
Identity, Skin, and Visibility
Melanoma is a skin cancer, and for many patients the relationship with their skin is complicated by the disease. Sun exposure, outdoor activities, the beach vacation that felt like freedom — all of these carry a shadow of causation that can become guilt. Cutaneous metastases that are visible on the face, scalp, or limbs are a constant visible reminder of disease that internal organ cancers do not impose. Address this: "Your body is not your enemy. The skin you lived in and loved the sun with is the same skin — the cancer is the intruder, not you." For patients with visible cutaneous or in-transit mets, offer wound care that minimizes visual distress, discuss palliative radiation for cosmetically distressing lesions, and ensure the patient has control over who sees and touches the affected areas.[40]
Family Structure & Caregiver Impact
Melanoma is diagnosed at a younger median age than many cancers — young spouses, young children, active professional lives interrupted. The family structure often includes school-age children who need age-appropriate explanation of what is happening to their parent. Caregiver burden is amplified by the brain met personality changes, the complexity of managing IO toxicity medications, and the emotional weight of the near-miss narrative. Screen caregivers for burnout using the Zarit Burden Interview or equivalent. Refer to social work at enrollment, not at crisis. Ensure respite care is offered before it is desperately needed.[42]
Clinical Pearl
"Melanoma families are often highly educated about the disease — they've lived inside the statistics and clinical trials for months or years. Don't condescend. Meet them where they are. Some of them know more about checkpoint inhibitors than your average hospitalist. Use that knowledge as an asset in the care plan, not a challenge to your authority."
"The near-miss grief is the hardest thing I manage in melanoma. The wife who says 'But the doctor said fifty-two percent. We were supposed to be in the fifty-two percent.' And she's right — they were supposed to be. There's no clinical tool for that grief. You just sit with it. You say the thing: 'You deserved to be in the group that made it.' And then you sit in the silence that follows, because that silence is the most therapeutic thing you have."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Your loved one has metastatic melanoma that has spread to other parts of the body, including possibly the brain. You may already know a great deal about this disease — many melanoma families do. You may know that immunotherapy works remarkably well for many people, and that it did not work the way everyone hoped for your person. That is a grief we want to name: the near-miss of a treatment that was genuinely your best chance. What matters now is comfort, presence, and managing the symptoms that melanoma creates — particularly the effects of brain involvement and the side effects of prior treatments that may still need attention. Our team is here to help with all of it.
What You May See
- Personality or behavior changes: Irritability, impulsivity, saying things out of character — this is the brain metastases affecting the areas that control behavior and personality. It is the disease, not your person choosing this. Report new or worsening changes to the nurse.
- Memory and confusion: Forgetting recent events, getting disoriented in familiar places, difficulty with word-finding. This is neurological involvement. Keep routines simple and consistent. Report changes to the nurse — a medication adjustment may help.
- Seizures: Possible without warning in patients with brain metastases. Your nurse has reviewed the emergency medication protocol with you. Know where the medication is and how to give it. A seizure lasting more than 2–3 minutes needs the medication. Call the nurse after giving it.
- Fatigue that is profound and progressive: Sleeping most of the day is expected at this stage. Rest is appropriate. Your presence beside them while they sleep matters — they may hear you even when they cannot respond.
- Changes in liver function: Yellowing of the skin and eyes (jaundice), abdominal swelling, increasing confusion if liver metastases are progressing. Call the nurse if you notice these changes.
- Ongoing symptoms from prior cancer treatment: Diarrhea from immunotherapy-related colitis, joint pain, thyroid medication needs. These are from the immunotherapy and require ongoing management — the nurse is managing these alongside the cancer symptoms.
How You Can Help
- Know the seizure protocol: The emergency medication is at the bedside, drawn and labeled. A seizure lasting more than 2–3 minutes needs the medication. You can do this. The nurse has shown you how. Call the nurse after administering it.
- Keep the dexamethasone schedule exactly as prescribed: Do not miss doses. The brain function you are seeing — speech, movement, alertness — depends on this medication. Call the nurse before changing or stopping it for any reason.
- Continue all hormone replacement medications: Thyroid medication (levothyroxine) and cortisol replacement (hydrocortisone) if prescribed are permanent replacements from prior immunotherapy treatment. Stopping them causes a different kind of crisis. Do not stop without nurse guidance.
- Report personality changes or sudden worsening confusion immediately: This may be a dose adjustment opportunity. Do not wait for the next scheduled visit. Call the nurse.
- Be patient with communication difficulties: If your person has trouble finding words or following conversation, slow down, use simple sentences, and be comfortable with silence. They may understand more than they can express.
- Take care of yourself: Caregiving for a person with brain metastases is exhausting in ways that other illnesses are not. The personality changes, the medication complexity, the unpredictability — this is heavy. Call us when you need support, not just when the patient needs something.
📞 Call the nurse immediately if you see:
Seizure lasting more than 2–3 minutes (give the midazolam first, then call) · Sudden severe headache with vomiting or loss of consciousness (possible brain bleed — give midazolam if seizure occurs, keep patient safe, call immediately) · Sudden inability to speak, move one side of the body, or sudden vision loss (possible brain met event — call immediately) · New confusion much worse than baseline (could be brain edema — may need dexamethasone dose adjustment) · High fever with shaking chills (possible infection — especially if on steroids which mask fever) · Severe abdominal pain or bloody diarrhea (possible IO colitis flare — do not treat at home) · Signs of adrenal crisis if on hydrocortisone: sudden weakness, vomiting, confusion, low blood pressure (give stress-dose hydrocortisone if trained, call immediately)
🙏 You are doing something extraordinarily difficult — caring for someone you love through a disease that almost gave you more time together. That "almost" may be the hardest part. Your presence at the bedside is not passive. Research consistently shows that patients with engaged family caregivers have better symptom control, less anxiety, and more peaceful deaths. You are part of the treatment team. What you are doing matters more than you know.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01IO immune toxicities are active clinical problems at enrollment. I cannot say this loudly enough. When you admit a melanoma patient, your intake form needs to include specific questions: Have you had diarrhea from immunotherapy? Have you been on steroids for colitis, pneumonitis, or hepatitis? Are you taking thyroid medication or hydrocortisone that was started because of immunotherapy? What is your current steroid dose and what is the plan for tapering it? Do not inherit a patient on dexamethasone or prednisone without knowing exactly why, what the target dose is, and what the taper plan is. Abrupt discontinuation of steroids in a patient with IO-related adrenal insufficiency causes crisis — hypotension, vomiting, confusion. It is preventable. It is your job to prevent it.
- 02Dexamethasone taper for brain mets is not a calendar protocol. It is a neurological function protocol. The dose that maintains speech, motor function, or cognition is the right dose. I have had well-meaning nurses taper dexamethasone because "the textbook says to taper at week four" and the patient lost the ability to speak overnight. Taper when neurological status allows. If you increase the dose and function returns, that function is steroid-dependent and the patient needs that dose. Do not reduce because a protocol says to. Reduce because the patient's brain is telling you it's safe to reduce. And document every change in neurological function with every dose change — that documentation is the taper guide.
- 03Melanoma brain mets bleed. This is different from most brain metastases. Melanoma has a specific propensity for hemorrhagic events because of the vascularity of the tumors. From day one of enrollment for any patient with brain mets, midazolam is at the bedside, drawn and labeled. Not in the comfort kit bag. Not in the medication box in the kitchen. At the bedside, drawn, labeled, with the dose written on the syringe. The family knows what sudden headache and sudden loss of consciousness means. You have had the conversation. If you have not, you have left a family unprepared for a potentially traumatic event that could happen at 3 AM when you are not there. Have the conversation at enrollment. Not at the first sign of trouble.
- 04BRAF inhibitor continuation is not the same as choosing treatment over comfort. This is one of the most nuanced clinical decisions in hospice, and I've watched it go wrong in both directions. Some teams reflexively stop all cancer-directed therapy at hospice enrollment — and the BRAF-mutant patient with stable disease on dabrafenib + trametinib progresses rapidly because you took away the drug that was working. Other teams are so uncomfortable with continuing "treatment" in hospice that they avoid the conversation entirely. Here's the reality: if your melanoma patient is on oral targeted therapy with stable disease and chooses hospice for quality-of-life reasons, that pill may stay. Document it as a comfort decision, coordinated with oncology. It is not incompatible with hospice goals. It is precision medicine applied to the comfort setting.
- 05The near-miss grief needs to be named. Melanoma patients know the numbers. They know that 52% of patients on nivolumab + ipilimumab are alive at 5 years. They know they were supposed to be in that group. And now they're not. That is a mathematically specific grief that you cannot address with generic hospice language about "acceptance" and "peace." You have to say the specific thing: "You went into this knowing the odds were genuinely good. You deserved to be in the group that made it." That sentence, said with eye contact and conviction, is one of the most therapeutically powerful things you can say to a progressing melanoma patient. Say it. Do not avoid it because it is uncomfortable. The patient is already living in the discomfort. Your job is to join them there.
- 06Seizure preparedness in melanoma brain mets is non-negotiable. Levetiracetam daily for prophylaxis. Midazolam at the bedside for rescue. The family has been trained to administer it. They have practiced with a demo syringe. They know what a seizure looks like. They know the difference between "wait and watch" (a seizure that stops in under 2 minutes) and "give the medication now" (a seizure lasting more than 2–3 minutes). They know to call the nurse after giving it. They know not to put anything in the patient's mouth. If your patient with brain mets does not have this protocol in place by the end of your first visit, you are not done with your first visit. Go back.
- 07Brain met personality changes devastate families in a way that physical decline does not. When a person you love becomes someone you don't recognize — impulsive, disinhibited, flat, forgetful — that is a form of loss that happens before death. The clinical term is ambiguous loss. The family term is "I already lost him." Validate it. Say: "The person you are watching right now is not the person you married. That change is the brain metastases, and it is a real loss that you are allowed to grieve right now — not just when they die." Families need permission to grieve the living person. Give them that permission explicitly. And refer to your social worker and chaplain — this is their clinical territory and they are better at it than you are.
- 08Racial disparities in melanoma are real and they are your problem to help fix. Acral lentiginous melanoma — the type that occurs on palms, soles, and under nails — accounts for about 70% of melanoma in Black, Hispanic, and Asian patients. It is diagnosed later, at more advanced stages, with worse outcomes — not because of biology but because clinicians do not look for melanoma in darker-skinned patients with the same urgency. By the time these patients reach hospice, they have often experienced a healthcare system that failed them at the screening and early-diagnosis level. Be aware of this history. Ensure equitable pain management. Do not assume that cultural silence about pain means absence of pain. And understand that the patient's relationship with the medical system may carry justified skepticism. Earn their trust by being competent, consistent, and present.
- 09Caregivers of melanoma patients burn out differently. The complexity is relentless: managing a dexamethasone taper, remembering when to give levetiracetam, knowing where the midazolam is, watching personality changes, navigating the emotional whiplash of "your treatment is working" followed by "we've run out of options," managing ongoing IO toxicity symptoms, and processing their own near-miss grief alongside the patient's. Screen for caregiver burnout at every visit — not with a formal tool necessarily, but by asking: "How are you sleeping? When was the last time you left the house for yourself? Is this becoming too much?" Offer respite before they ask for it. And when a caregiver says "I'm fine" while looking exhausted, believe their face, not their words.
- 10In the end, melanoma hospice is about being present with the weight of what almost was. Every melanoma patient in hospice is a person who lived through an era where their disease became curable for many — and they were not among the many. That is a specific grief. The brain mets, the IO toxicities, the BRAF inhibitors, the dexamethasone — those are the clinical problems, and you will manage them well because you are trained and you are competent. But the thing that makes melanoma hospice different from every other diagnosis on this list is the weight of the near-miss. Your clinical excellence is necessary. But what the patient and family will remember is whether you sat in that room and acknowledged what almost was. Do the clinical work perfectly. And then be human. Be present. Say the hard thing. Don't leave it to the next visit — for melanoma patients, there may not be one.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
2
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
3
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
4
Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009;16(3):248-255.
5
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the AJCC 8th edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
6
Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol. 2003;48(5):679-693.
7
Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
8
Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma (MSLT-II). N Engl J Med. 2017;376(23):2211-2222.
9
Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-4023.
10
Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-3190.
11
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421.
12
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline. J Clin Oncol. 2018;36(17):1714-1768.
13
Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28-44.
14
Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ. 2012;345:e4757.
15
Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44(2):99-106.
16
Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018-1021.
17
Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145(4):427-434.
18
Mahendraraj K, Sidhu K, Lau CS, et al. Malignant melanoma in African-Americans: a population-based clinical outcomes study involving 1106 African-American patients from the SEER database (1988-2011). Medicine. 2017;96(15):e6258.
19
Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239-1251.
20
Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma (RELATIVITY-047). N Engl J Med. 2022;386(1):24-34.
21
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626-636.
22
Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-615.
23
Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-395.
24
Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (ABC). Lancet Oncol. 2018;19(5):672-681.
25
Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol. 2014;32(26):2913-2919.
26
Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435-1448.
27
Hershman DL, Unger JM, Greenlee H, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer (SWOG S1200). JAMA. 2018;320(2):167-176.
28
Carlson LE, Doll R, Stephen J, et al. Randomized controlled trial of Mindfulness-Based Cancer Recovery versus Supportive Expressive Group Therapy for distressed survivors of breast cancer (MINDSET). J Clin Oncol. 2013;31(25):3119-3126.
29
Marx W, Ried K, McCarthy AL, et al. Ginger — mechanism of action in chemotherapy-induced nausea and vomiting: a review. Crit Rev Food Sci Nutr. 2017;57(1):141-146.
30
Innominato PF, Lim AS, Palesh O, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016;24(3):1097-1105.
31
Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis. J Med Food. 2016;19(8):717-729.
32
Molfino A, Gioia G, Fanelli FR, Muscaritoli M. The role for dietary omega-3 fatty acids supplementation in older adults. Nutrients. 2014;6(10):4058-4072.
33
Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94(16):1247-1249.
34
Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial (ECOG-ACRIN EA6134). J Clin Oncol. 2023;41(2):186-197.
35
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma (CheckMate 067): 6.5-year results. J Clin Oncol. 2022;40(2):99-110.
36
Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103-114.
37
Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years after: past, present, and future developments. J Pain Symptom Manage. 2017;53(3):630-643.
38
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens. JAMA Oncol. 2018;4(2):173-182.
39
Kasparian NA, McLoone JK, Butow PN. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review. Arch Dermatol. 2009;145(12):1415-1427.
40
Cornish D, Holterhues C, van de Poll-Franse LV, et al. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi51-vi58.
41
Boss P. Ambiguous Loss: Learning to Live with Unresolved Grief. Harvard University Press. 1999.
42
Girgis A, Lambert S, Johnson C, et al. Physical, psychosocial, relationship, and economic burden of caring for people with cancer: a review. J Oncol Pract. 2013;9(4):197-202.
43
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
44
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
45
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
46
Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785-792.
47
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
48
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017.
49
Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813-823.
50
Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36-49.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.